Amitiza(Lubiprostone)
Medicare prescription drug cost, prescriptions and prescribers, 2024
$2.9M
Medicare cost, 2024
$2.9M
Medicare cost, 2024
Medicare drug plans spent $2.9 million on Amitiza (lubiprostone) in 2024, for 6,882 prescriptions and refills filled by 2,367 patients. Spending fell 65% from 2023 to 2024. New York accounts for the most spending ($333,522, 11% of the total).
Medicare cost, 2024
$2.9M
-65.4% from 2023
Prescriptions
6,882
$422.58 per claim
Patients
2,367
2,449 prescribers
Total spending, 2024
$2.9M
$1,228.88 per patient
Questions and answers
How much does Medicare spend on Amitiza?
Medicare prescription drug plans paid $2.9M for Amitiza in 2024, for 6,882 prescriptions and refills to 2,367 patients (down 65.4% from 2023). The average cost per claim was $422.58.
Which state spends the most on Amitiza?
New York had the highest Medicare cost for Amitiza in 2024: $334K for 815 claims, followed by California ($266K).
Who prescribes Amitiza the most?
Nicole K Nichols, nurse practitioner in Saint Louis, MO, had the highest Medicare cost for Amitiza in 2024: 13 claims costing $9,088.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Amitiza was $2.9M in 2024, after a high of $279.3M in 2020.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Amitiza, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Nicole K Nichols Saint Louis, MO | Nurse Practitioner | 13 | Under 11 | $9,088 |
| Victor Lyapis Colusa, CA | General Practice | 38 | Under 11 | $9,003 |
| Inna Gordin Brooklyn, NY | Internal Medicine | 23 | Under 11 | $8,882 |
| Scott Estabrook Danbury, CT | Gastroenterology | 12 | Under 11 | $7,864 |
| Gavriel Fuzaylov Forest Hills, NY | Internal Medicine | 19 | Under 11 | $6,917 |
| Scott M Smukalla New York, NY | Gastroenterology | 19 | Under 11 | $6,868 |
| Dina Sverdlov San Mateo, CA | Internal Medicine | 24 | Under 11 | $6,854 |
| 1174732663 | Internal Medicine | 28 | Under 11 | $6,751 |
| Konstantin Peysin Brooklyn, NY | Internal Medicine | 22 | Under 11 | $6,603 |
| Grigoriy E Gurvits New York, NY | Gastroenterology | 23 | Under 11 | $6,207 |
| Summer A Hinthorne Normal, IL | Nurse Practitioner | 12 | Under 11 | $5,440 |
| Anabelle Ramos Rosado Belen, NM | Family Practice | 14 | Under 11 | $5,404 |
| Jordan M Dunitz Minneapolis, MN | Pulmonary Disease | 13 | Under 11 | $5,281 |
| Timothy C Kleinschmidt Duluth, MN | Internal Medicine | 17 | Under 11 | $5,236 |
| Jarod J Marcotte Leavenworth, KS | Physician Assistant | 13 | Under 11 | $5,199 |
| Zarine Ter-Poghosyan Burbank, CA | Family Practice | 13 | Under 11 | $5,076 |
| Vamsi K Kantamaneni Decatur, GA | Gastroenterology | 14 | Under 11 | $5,048 |
| Yervand Set Agayan Glendale, CA | Family Practice | 13 | Under 11 | $5,039 |
| Timothy C Dickey Columbia, TN | Nurse Practitioner | 13 | Under 11 | $5,004 |
| Bryan A Hubl Hebron, NE | Family Practice | 13 | Under 11 | $4,969 |
| Fernando T Itable Milwaukee, WI | Internal Medicine | 13 | Under 11 | $4,941 |
| Kathryn B Overberg Louisville, KY | Nurse Practitioner | 13 | Under 11 | $4,829 |
| Anisaa W Romano Perry Andrews, NC | Family Practice | 12 | Under 11 | $4,816 |
| Humera Ahmed Frisco, TX | Internal Medicine | 12 | Under 11 | $4,757 |
| Soo W Kang Buena Park, CA | Internal Medicine | 13 | Under 11 | $4,740 |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 14,059 | 49,821 | 15,665 | $23.1M |
| 2023 | 5,722 | 18,581 | 5,732 | $8.4M |
| 2024 | 2,449 | 6,882 | 2,367 | $2.9M |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Takeda Pharmace | 4,909 | $1.9M |
| Mallinck-Specgx | 1,978 | $1.0M |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 3
- RxNorm concept IDs
- 616578, 617768, 794639, 794641
- Application numbers
- NDA021908
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 9,556 side-effect reports named lubiprostone, the active ingredient of Amitiza (reports from 2006 on). 6,379 of them (66.8%) were serious, 972 named a death and 3,148 named a hospital stay. The reactions named most often were nausea, dyspnoea and diarrhoea. 2,207 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
9,556
476 in 2025 (+7.7% from 2024)
Serious
66.8%
6,379 reports
Deaths named
972
10.2% of reports
Hospital stays
3,148
32.9% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Amitiza?
9,556 reports from 2006 through September 2026 named lubiprostone, the active ingredient of Amitiza. 6,379 of them (66.8%) were serious, 972 named a death and 3,148 named a hospital stay.
What are the most reported side effects of Amitiza?
803 reports named nausea, the reaction named most often, followed by dyspnoea (641) and diarrhoea (633). In the last 5 years the reaction named most often was diarrhoea (164 reports). A report can name several reactions.
How many side-effect reports named Amitiza in 2025?
476 reports were received in 2025 (+7.7% from 2024). 2026 so far: 415 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Amitiza caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Amitiza caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with lubiprostone: Lubiprostone
- Drug approvals (5 approvals on file for lubiprostone) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (lubiprostone) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.